Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.22.2.2
SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The following table presents information by reportable operating segment for the three and six months ended June 30, 2022 and 2021 (in thousands):
Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Three months ended June 30, 2022:
Product sales, net $ 4,138  $ —  $ 4,138 
Gross profit $ 1,270  $ —  $ 1,270 
Research and development expense 84  18  102 
Selling, general and administrative expense 3,474  9  3,483 
Operating loss $ (2,288) $ (27) $ (2,315)
Three months ended June 30, 2021:
Product sales, net $ 5,128  $ —  $ 5,128 
Gross profit $ 2,290  $ —  $ 2,290 
Research and development expense 126  99  225 
Selling, general and administrative expense 5,565  10  5,575 
Operating loss $ (3,401) $ (109) $ (3,510)

Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Six months ended June 30, 2022:
Product sales, net $ 8,585  $ —  $ 8,585 
Gross profit $ 2,426  $ —  $ 2,426 
Research and development expense 201  22  223 
Selling, general and administrative expense 5,993  40  6,033 
Operating loss $ (3,768) $ (62) $ (3,830)
Six months ended June 30, 2021:
Product sales, net $ 9,972  $ —  $ 9,972 
Gross profit $ 4,648  $ —  $ 4,648 
Research and development expense 254  157  411 
Selling, general and administrative expense 10,835  25  $ 10,860 
Operating loss $ (6,441) $ (182) $ (6,623)